Page 49 - Read Online
P. 49

Page 334                                Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37

             Ref.   [14]      [34]     [40]      [13]       [63]       [37]   [66]        [29]



             Clinical outcomes  No association of   ABCC2 c.-24C>T and   c.3972C>T variants with   gastrointestinal adverse   No association of ABCC2   c.-24C>T, c.1249G>A,   1446C>G and   c.3972C>T variants with   AR or adverse events  No association of ABCC2   c.-24C>T, c.1249G>A,   c.3972C>T and  c.4544G>A variants with   AR or adverse events






                 -                   events                 -
             Pharmacokinetics  No association of  ABCC2 c.-24C>T variant   with MPA or MPAG   pharmacokinetics  -  No association of ABCC2 -  c.-24C>T, c.1249G>A,   3563T>A and   c.3972C>T variants with   MPA pharmacokinetics  -  ABCC2 c.-24T allele   was associated with   lower MPA AUC, on   cyclosporine-free   treatment  No association of ABCC2 - c.-24T variant with MPA   or MPAG exposure   (AUC 4-12  or AUC 0-12 )  No association of ABCC2 - c.-24C>T and c.3972C>T  vari








            Immunosuppressive   regimen  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids  At a point between 3-6   months  MMF  Cyclosporine Tacrolimus  Sirolimus  Up to 115-month follow-  up  MMF  Cyclosporine  Tacrolimus  Corticosteroids  Sixty-day follow-up  MMF  Cyclosporine  Tacrolimus  mTOR inhibitor   Corticosteroids  One-year follow-up  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids  Three-month follow-up  MMF Cyclosporine Prednisone  MMF  Cyc












             Population       256 adult patients   89 pediatric patients
                 185 patients  (France)  (France)  (France)  (France)  55 adult patients  (Spain)  37 adult patients  (China)  56 adult patients   189 adult patients  (France)






             Study design  Prospective (included   multicenter Apomygre   study)  Retrospective  Prospective, multicenter  Retrospective (Transgene 218 adult patients   study)  Prospective, multicenter   (Symphony study)  Prospective,  Multicenter  (Case-control)  Prospective, multicenter   (Symphony study)  Prospective, multicenter   (Dominos study)








             Allele frequency  c.-24T: 23%  c.-24T: 24%  c.3972T: 39%  c.-24T:19% c.1249A: 19%  3563A: 10%   c.3972T:35%  c.-24T: 19%  c.1249A: 19%  1446G: 0.7%   c.3972T: 35%  c.-24T: 21%  c.3972T: 23%  c.-24T: 28%  c.-24T: 19%  c.3972T: 36%  c.-24T: 17%   c.1249A: 21%  c.3972T: 39%  c.4544A: 8%











             Variant






             Gene
   44   45   46   47   48   49   50   51   52   53   54